The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4574-4574
Author(s):  
Z. A. Dotan ◽  
K. Sathyamoorthy ◽  
F. J. Bianco ◽  
A. J. Stephenson ◽  
J. A. Eastham ◽  
...  

4574 Background: Physicians often order periodic bone scans to check for metastases in patients treated with androgen ablation therapy (ADT) for rising PSA (biochemical recurrence; BCR) following radical prostatectomy. However, most of these scans are negative. We studied patient characteristics to build a predictive model for a positive scan (+BS) in that setting. Methods: From our prostate cancer database we identified all patients with detectable PSA after radical prostatectomy that were treated by ADT for BCR only. There were 511 BS performed in patients treated with ADT for BCR. Among them, 151 BS were performed for patients with BCR only with out previous evidence of bone metastases (1–8 BS for patient with median of one). We analyzed the following potential predictors for a positive bone scan at the time of each bone scan: preoperative PSA, history of neoadjuvant ADT (NA-ADT), time to BCR, pathologic findings (surgical margin, extracapsular extension, seminal vesicle invasion, lymph node metastases, and Gleason score), PSA before the BS (trigger PSA), PSA doubling time and time from BCR to BS. The results were incorporated into a predictive model. Results: Among the 151 BS, only 35 (23%) were positive for metastases. In multivariate analysis, only trigger PSA (P < 0.001, OR 1.84) and NA-ADT (P = 0.02, OR 1.32) predicted a +BS. Probability of +BS according to PSA of 0–2, 2.1–4, 4.1–10, 10.1–20 and above 20.1 were 4.7%, 15.3%, 29.6%, 46.1% and 63.3% respectively. A nomogram was constructed for predicting the probability of +BS, and was found to have a concordance index of 0.83. Calibration of the nomogram according to bootstrap analysis showed that the nomogram is reasonably accurate. Conclusions: Trigger PSA and a history of neoadjuvant ADT were associated with a +BS. Omitting scans in low-risk patients could reduce substantially the number of scans ordered. No significant financial relationships to disclose.

2005 ◽  
Vol 23 (9) ◽  
pp. 1962-1968 ◽  
Author(s):  
Zohar A Dotan ◽  
Fernando J. Bianco ◽  
Farhang Rabbani ◽  
James A. Eastham ◽  
Paul Fearn ◽  
...  

Purpose Physicians often order periodic bone scans (BS) to check for metastases in patients with an increasing prostate-specific antigen (PSA; biochemical recurrence [BCR]) after radical prostatectomy (RP), but most scans are negative. We studied patient characteristics to build a predictive model for a positive scan. Patients and Methods From our prostate cancer database we identified all patients with detectable PSA after RP. We analyzed the following features at the time of each bone scan for association with a positive BS: preoperative PSA, time to BCR, pathologic findings of the RP, PSA before the BS (trigger PSA), PSA kinetics (PSA doubling time, PSA slope, and PSA velocity), and time from BCR to BS. The results were incorporated into a predictive model. Results There were 414 BS performed in 239 patients with BCR and no history of androgen deprivation therapy. Only 60 (14.5%) were positive for metastases. In univariate analysis, preoperative PSA (P = .04), seminal vesicle invasion (P = .02), PSA velocity (P < .001), and trigger PSA (P < .001) predicted a positive BS. In multivariate analysis, only PSA slope (odds ratio [OR], 2.71; P = .03), PSA velocity (OR, 0.93; P = .003), and trigger PSA (OR, 1.022; P < .001) predicted a positive BS. A nomogram for predicting the bone scan result was constructed with an overfit-corrected concordance index of 0.93. Conclusion Trigger PSA, PSA velocity, and slope were associated with a positive BS. A highly discriminating nomogram can be used to select patients according to their risk for a positive scan. Omitting scans in low-risk patients could reduce substantially the number of scans ordered.


1996 ◽  
Vol 3 (3) ◽  
pp. 171-177 ◽  
Author(s):  
F Lee ◽  
D B Siders ◽  
T A McHugh ◽  
M H Solomon ◽  
D M Mayman

2014 ◽  
Vol 28 (10) ◽  
pp. 1629-1639 ◽  
Author(s):  
Yingqiu Xie ◽  
Wenfu Lu ◽  
Shenji Liu ◽  
Qing Yang ◽  
Brett S. Carver ◽  
...  

Castration-resistant prostate cancer (PCa) (CRPC) is relapse after various forms of androgen ablation therapy and causes a major mortality in PCa patients, yet the mechanism remains poorly understood. Here, we report the nuclear form of mesenchymal epithelial transition factor (nMET) is essential for CRPC. Specifically, nMET is remarkably increased in human CRPC samples compared with naïve samples. Androgen deprivation induces endogenous nMET and promotes cell proliferation and stem-like cell self-renewal in androgen-nonresponsive PCa cells. Mechanistically, nMET activates SRY (sex determining region Y)-box9, β-catenin, and Nanog homeobox and promotes sphere formation in the absence of androgen stimulus. Combined treatment of MET and β-catenin enhances the inhibition of PCa cell growth. Importantly, MET accumulation is detected in nucleus of recurrent prostate tumors of castrated Pten/Trp53 null mice, whereas MET elevation is predominantly found in membrane of naïve tumors. Our findings reveal for the first time an essential role of nMET association with SOX9/β-catenin in CRPC in vitro and in vivo, highlighting that nuclear RTK activate cell reprogramming to drive recurrence, and targeting nMET would be a new avenue to treat recurrent cancers.


Sign in / Sign up

Export Citation Format

Share Document